JHS Svendgaard Laboratories Q3FY26 Financial Results Published
JHS Svendgaard Laboratories reported Q3FY26 results. Standalone profit after tax was ₹789 lacs for the quarter and ₹164.83 lacs for nine months. Consolidated profit after tax was ₹768.9 lacs for the quarter and ₹164.63 lacs for nine months.
Financial results are material information for investors and can impact stock price, hence the impact is considered medium.
The announcement is a routine disclosure of financial results and does not contain any information that would suggest a positive or negative outlook.
JHS Svendgaard Laboratories Limited has announced its financial results for the quarter and nine months ended December 31, 2025. The company has published extracts of these results in the Business Standard newspaper on February 12, 2026, in both English and Hindi editions.
These financial results were reviewed by the Audit Committee and approved by the Board of Directors in their meeting held on February 10, 2026. The detailed format of the financial results is available on the company's website, www.svendgaard.com, as well as on the websites of the Bombay Stock Exchange (BSE) and the National Stock Exchange (NSE).
The announcement also includes key financial figures for the standalone and consolidated results. For the quarter ended December 31, 2025, the standalone total income from operations was ₹28,531 lacs, with a profit after tax of ₹789 lacs. For the nine months ended December 31, 2025, the standalone total income was ₹71,721 lacs, with a profit after tax of ₹164.83 lacs.
On a consolidated basis for the quarter ended December 31, 2025, total income from operations was ₹232,678 lacs, with a profit after tax of ₹768.9 lacs. For the nine months ended December 31, 2025, consolidated total income was ₹689,990 lacs, with a profit after tax of ₹164.63 lacs.
What to do with a filing like this
JHS Svendgaard Laboratories Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by JHS Svendgaard Laboratories Limited. Read the original for the full detail.